TY - JOUR AU - Molnár, Tihamér AU - Horváth, Andrea AU - Molnárné Szabó, Zsuzsanna AU - Vámos, Zoltán AU - Dóczi, Tamás Péter AU - Illés, Zsolt László TI - Detection of silent cerebral microcirculatory abnormalities in patients with manifest ischemic coronary disease: a perfusion brain MRI study combined with dipyridamole stress JF - SCANDINAVIAN CARDIOVASCULAR JOURNAL J2 - SCAND CARDIOVASC J VL - 55 PY - 2021 IS - 2 SP - 97 EP - 101 PG - 5 SN - 1401-7431 DO - 10.1080/14017431.2020.1821911 UR - https://m2.mtmt.hu/api/publication/31594638 ID - 31594638 LA - English DB - MTMT ER - TY - JOUR AU - Barajas, Ramon F. AU - Hamilton, Bronwyn E. AU - Schwartz, Daniel AU - McConnell, Heather L. AU - Pettersson, David R. AU - Horváth, Andrea AU - Szidonya, Laszlo AU - Varallyay, Csanad G. AU - Firkins, Jenny AU - Jaboin, Jerry J. AU - Kubicky, Charlotte D. AU - Raslan, Ahmed M. AU - Dogan, Aclan AU - Cetas, Justin S. AU - Ciporen, Jeremy AU - Han, Seunggu J. AU - Ambady, Prakash AU - Muldoon, Leslie L. AU - Woltjer, Randy AU - Rooney, William D. AU - Neuwelt, Edward A. TI - Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression JF - NEURO-ONCOLOGY J2 - NEURO-ONCOLOGY VL - 21 PY - 2019 IS - 4 SP - 517 EP - 526 PG - 10 SN - 1522-8517 DO - 10.1093/neuonc/noy160 UR - https://m2.mtmt.hu/api/publication/31076668 ID - 31076668 AB - Background Noninvasively differentiating therapy-induced pseudoprogression from recurrent disease in patients with glioblastoma is prospectively difficult due to the current lack of a biologically specific imaging metric. Ferumoxytol iron oxide nanoparticle MRI contrast characterizes innate immunity mediated neuroinflammation; therefore, we hypothesized that combined ferumoxytol and gadolinium enhanced MRI could serve as a biomarker of glioblastoma pseudoprogression.Methods In this institutional review board-approved, retrospective study, we analyzed ferumoxytol and gadolinium contrast enhanced T1-weighted 3T MRI in 45 patients with glioblastoma over multiple clinical timepoints. Isocitrate dehydrogenase 1 (IDH-1) mutational status was characterized by exome sequencing. Sum of products diameter measurements were calculated according to Response Assessment in Neuro-Oncology criteria from both gadolinium and ferumoxytol enhanced sequences. Enhancement mismatch was calculated as the natural log of the ferumoxytol to gadolinium sum of products diameter ratio. Analysis of variance and Student's t-test assessed differences in mismatch ratios. P-value <0.05 indicated statistical significance.Results With the development of pseudoprogression we observed a significantly elevated mismatch ratio compared with disease recurrence (P < 0.01) within IDH-1 wild type patients. Patients with IDH-1 mutation demonstrated significantly reduced mismatch ratio with the development of pseudoprogression compared with disease recurrence (P < 0.01). Receiver operator curve analysis demonstrated 100% sensitivity and specificity for the use of mismatch ratios as a diagnostic biomarker of pseudoprogression.Conclusion Our study suggests that ferumoxytol to gadolinium contrast mismatch ratios are an MRI biomarker for the diagnosis of pseudoprogression in patients with glioblastoma. This may be due to the unique characterization of therapy-induced neuroinflammation. LA - English DB - MTMT ER - TY - JOUR AU - Varga, Edit AU - Pandur, Edina AU - Ábrahám, Hajnalka AU - Horváth, Andrea AU - Ács, Péter AU - Komoly, Sámuel AU - Miseta, Attila János AU - Sipos, Katalin TI - Cuprizone Administration Alters the Iron Metabolism in the Mouse Model of Multiple Sclerosis JF - CELLULAR AND MOLECULAR NEUROBIOLOGY J2 - CELL MOL NEUROBIOL VL - 38 PY - 2018 IS - 5 SP - 1081 EP - 1097 PG - 17 SN - 0272-4340 DO - 10.1007/s10571-018-0578-5 UR - https://m2.mtmt.hu/api/publication/3339994 ID - 3339994 AB - Cuprizone (CZ) is a widely used copper chelating agent to develop non-autoimmune animal model of multiple sclerosis, characterized by demyelination of the corpus callosum (CC) and other brain regions. The exact mechanisms of CZ action are still arguable, but it seems that the only affected cells are the mature oligodendrocytes, possibly via metabolic disturbances caused by copper deficiency. During the pathogenesis of multiple sclerosis, high amount of deposited iron can be found throughout the demyelinated areas of the brain in the form of extracellular iron deposits and intracellularly accumulated iron in microglia. In the present study, we used the accepted experimental model of 0.2% CZ-containing diet with standard iron concentration to induce demyelination in the brain of C57BL/6 mice. Our aim was to examine the changes of iron homeostasis in the CC and as a part of the systemic iron regulation, in the liver. Our data showed that CZ treatment changed the iron metabolism of both tissues; however, it had more impact on the liver. Besides the alterations in the expressions of iron storage and import proteins, we detected reduced serum iron concentration and iron stores in the liver, together with elevated hepcidin levels and feasible disturbances in the Fe-S cluster biosynthesis. Our results revealed that the CZ-containing diet influences the systemic iron metabolism in mice, particularly the iron homeostasis of the liver. This inadequate systemic iron regulation may affect the iron homeostasis of the brain, eventually indicating a relationship among CZ treatment, iron metabolism, and neurodegeneration. LA - English DB - MTMT ER - TY - JOUR AU - Varallyay, CG AU - Nesbit, E AU - Horváth, Andrea AU - Várallyay, Péter AU - Fu, R AU - Gahramanov, S AU - Muldoon, LL AU - Li, X AU - Rooney, WD AU - Neuwelt, EA TI - Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care. JF - JOURNAL OF MAGNETIC RESONANCE IMAGING J2 - JMRI - J MAGN RESON IM VL - 48 PY - 2018 IS - 2 SP - 441 EP - 448 PG - 8 SN - 1053-1807 DO - 10.1002/jmri.25943 UR - https://m2.mtmt.hu/api/publication/3325672 ID - 3325672 AB - BACKGROUND: Cerebral blood volume (CBV) mapping with a dynamic susceptibility contrast (DSC) perfusion technique has become a clinical tool in diagnosing and follow-up of brain tumors. Ferumoxytol, a long-circulating iron oxide nanoparticle, has been tested for CBV mapping, but the optimal dose has not been established. PURPOSE: To compare ferumoxytol DSC of two different doses to standard of care gadoteridol by analyzing time-intensity curves and CBV maps in normal-appearing brain regions. STUDY TYPE: Retrospective. SUBJECTS: Fifty-four patients with various brain disorders. FIELD STRENGTH/SEQUENCE: 3T MRI. DSC-MRI was performed with 0.1 mmol/kg gadoteridol and 1 day later with ferumoxytol in doses of 1 or 2 mg/kg. ASSESSMENT: Signal changes during first pass, relative CBV (rCBV) in normal-appearing thalamus, putamen, and globus pallidus, and contrast-to-noise ratio (CNR) of the CBV maps were compared between gadoteridol and various doses of ferumoxytol using an automated method. To subjectively assess the quality of the CBV maps, two blinded readers also assessed visual conspicuity of the putamen. STATISTICAL TESTS: Linear mixed effect model was used for statistical comparison. RESULTS: Compared to gadoteridol, 1 mg/kg ferumoxytol showed no difference in CNR (P = 0.6505), peak DeltaR2*, and rCBV in the putamen (P = 0.2669, 0.0871) or in the thalamus (P = 0.517, 0.9787); 2 mg/kg ferumoxytol increased peak DeltaR2* as well as the CNR (P < 0.0001), but also mildly increased rCBV in putamen and globus pallidus (P = 0.0005, 0.0012). Signal intensities during first pass remained highly above the noise level, with overlapping of 95% confidence intervals with noise only in 3 out of 162 tested regions. Compared to gadoteridol, the visual image quality showed mild improvement with 1 mg/kg (P = 0.02) and marked improvement with 2 mg/kg ferumoxytol (P < 0.0001). DATA CONCLUSION: 1 mg/kg ferumoxytol provides similar imaging results to standard gadoteridol for DSC-MRI, and 2 mg/kg has a benefit of increased CNR, but may also result in mildly increased rCBV values. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2018. LA - English DB - MTMT ER - TY - JOUR AU - Horváth, Andrea AU - Varallyay, CG AU - Schwartz, D AU - Toth, GB AU - Netto, JP AU - Barajas, R AU - Várallyay, Péter AU - Szidonya, L AU - Firkins, J AU - Youngers, E AU - Fu, R AU - Ambady, P AU - Bogner, Péter AU - Neuwelt, EA TI - Quantitative comparison of delayed ferumoxytol T1 enhancement with immediate gadoteridol enhancement in high grade gliomas JF - MAGNETIC RESONANCE IN MEDICINE J2 - MAGN RESON MED VL - 80 PY - 2018 IS - 1 SP - 224 EP - 230 PG - 7 SN - 0740-3194 DO - 10.1002/mrm.27028 UR - https://m2.mtmt.hu/api/publication/3300443 ID - 3300443 AB - PURPOSE: Delayed ferumoxytol enhancement on T1 -weighted images appears visually similar to gadoteridol enhancement. The purpose of this study was to quantitatively compare ferumoxytol T1 enhancement to gadoteridol enhancement with an objective, semi-automated method. METHODS: 206 sets of post-gadoteridol and 24 h post-ferumoxytol T1 -weighted scans from 58 high grade glioma patients were analyzed (9 pre-chemoradiation, 111 < 90 days post-chemoradiation, 21 > 90 days post-chemoradiation, 65 post-bevacizumab scans). Enhancement volumes and signal intensities normalized to normal appearing tissue proximal to enhancement were calculated with a semi-automated method. Enhancement cube root volumes (D) and signal intensities (SI) were compared between the 2 contrast agents, and relative difference of D and SI were compared in different treatment groups with multivariate analysis. Within patient differences in D and SI before and after treatment with bevacizumab or steroid were assessed in 26 patients in each treatment group. RESULTS: When compared to gadoteridol, ferumoxytol D was 13.83% smaller and SI was 7.24% lower (P < 0.0001). The relative differences in D and SI between the 2 contrast agents were not significantly different between treatment groups (P > 0.05). Relative difference in D and SI did not change significantly in response to bevacizumab (P = 0.5234 and P = 0.2442, respectively) or to steroid (P = 0.3774, P = 0.0741) in the within patient comparison. CONCLUSION: The correlation between the 2 contrast agents' enhancement size and signal intensity and their similar behavior in response to therapy suggest that ferumoxytol can be used for revealing enhancement in high grade glioma patients. Magn Reson Med, 2017. (c) 2017 International Society for Magnetic Resonance in Medicine. LA - English DB - MTMT ER - TY - GEN AU - Varga, Edit AU - Pandur, Edina AU - Ábrahám, H AU - Horváth, Andrea AU - Ács, P AU - Pap, Ramóna AU - Sipos, Katalin TI - A corpus callosumban és a májban bekövetkező vasanyagcsere változások cuprizone indukálta demielinizáció hatására egérben PY - 2017 UR - https://m2.mtmt.hu/api/publication/3251521 ID - 3251521 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Toth, GB AU - Varallyay, CG AU - Horváth, Andrea AU - Bashir, MR AU - Choyke, PL AU - Daldrup-Link, HE AU - Dósa, Edit AU - Finn, JP AU - Gahramanov, S AU - Harisinghani, M AU - Macdougall, I AU - Neuwelt, A AU - Vasanawala, SS AU - Ambady, P AU - Barajas, R AU - Cetas, JS AU - Ciporen, J AU - DeLoughery, TJ AU - Doolittle, ND AU - Fu, R AU - Grinstead, J AU - Guimaraes, AR AU - Hamilton, BE AU - Li, X AU - McConnell, HL AU - Muldoon, LL AU - Nesbit, G AU - Netto, JP AU - Petterson, D AU - Rooney, WD AU - Schwartz, D AU - Szidonya, L AU - Neuwelt, EA TI - Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. JF - KIDNEY INTERNATIONAL J2 - KIDNEY INT VL - 92 PY - 2017 IS - 1 SP - 47 EP - 66 PG - 20 SN - 0085-2538 DO - 10.1016/j.kint.2016.12.037 UR - https://m2.mtmt.hu/api/publication/3216966 ID - 3216966 AB - Contrast-enhanced magnetic resonance imaging is a commonly used diagnostic tool. Compared with standard gadolinium-based contrast agents, ferumoxytol (Feraheme, AMAG Pharmaceuticals, Waltham, MA), used as an alternative contrast medium, is feasible in patients with impaired renal function. Other attractive imaging features of i.v. ferumoxytol include a prolonged blood pool phase and delayed intracellular uptake. With its unique pharmacologic, metabolic, and imaging properties, ferumoxytol may play a crucial role in future magnetic resonance imaging of the central nervous system, various organs outside the central nervous system, and the cardiovascular system. Preclinical and clinical studies have demonstrated the overall safety and effectiveness of this novel contrast agent, with rarely occurring anaphylactoid reactions. The purpose of this review is to describe the general and organ-specific properties of ferumoxytol, as well as the advantages and potential pitfalls associated with its use in magnetic resonance imaging. To more fully demonstrate the applications of ferumoxytol throughout the body, an imaging atlas was created and is available online as supplementary material. LA - English DB - MTMT ER - TY - THES AU - Horváth, Andrea TI - Diffusion weighted imaging in the normal appearing white matter of glioma patients PY - 2016 UR - https://m2.mtmt.hu/api/publication/31798854 ID - 31798854 LA - English DB - MTMT ER - TY - JOUR AU - Nagy, Szilvia Anett AU - Horváth, Réka AU - Perlaki, Gábor AU - Orsi, Gergely AU - Barsi, Péter AU - John, Flóra AU - Horváth, Andrea AU - Kovács, Norbert AU - Bogner, Péter AU - Ábrahám, Hajnalka AU - Bóné, Beáta AU - Trischlerné Gyimesi, Csilla AU - Dóczi, Tamás Péter AU - Janszky, József Vladimír TI - Age at onset and seizure frequency affect white matter diffusion coefficient in patients with mesial temporal lobe epilepsy JF - EPILEPSY & BEHAVIOR J2 - EPILEPSY BEHAV VL - 61 PY - 2016 SP - 14 EP - 20 PG - 7 SN - 1525-5050 DO - 10.1016/j.yebeh.2016.04.019 UR - https://m2.mtmt.hu/api/publication/3047088 ID - 3047088 N1 - * Megosztott szerzőség LA - English DB - MTMT ER - TY - JOUR AU - Horváth, Andrea AU - Csanad, Varallyay AU - Peter, Varallyay AU - Daniel, Schwartz AU - Prakash, Ambady AU - Bogner, Péter AU - Edward, Neuwelt TI - Comparison of gadolinium and ferumoxytol enhancement changes in response to Avastin in high grade glioma patients JF - INSIGHTS INTO IMAGING J2 - INSIGHTS IMAGING VL - 7 PY - 2016 IS - 1 Suppl. SP - S223 SN - 1869-4101 DO - 10.1007/s13244-016-0475-8 UR - https://m2.mtmt.hu/api/publication/3035474 ID - 3035474 LA - English DB - MTMT ER -